New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40844618.
- Also identified by DOI 10.14309/ajg.0000000000003742.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Janus kinase inhibitors (JAKi) are small-molecule therapies used in inflammatory bowel disease (IBD). We describe 8 patients with IBD who developed an eczematous eruption, presumed atopic dermatitis (AD), after stopping JAKi therapy. This case series describes 8 patients with IBD who developed de novo AD after withdrawal of JAKi therapy. Median time to AD onset was 7 days (interquartile range 2-12). Two cases with biopsy-confirmed AD resolved after reinitiation of JAKi therapy and adjunct AD treatments. A subset of patients with IBD may have latent susceptibility to AD, unmasked by therapy cessation and potentially triggered by an immune rebound effect.
Medical subject headings
- Dermatitis, Atopic
- Drug Eruptions
- Eczema
- Inflammatory Bowel Diseases
- Janus Kinase Inhibitors